Besides, a number of recent findings indicate that genetic depletion or pharmacological inhibition of RPN11 strongly antagonizes the growth of several types of cancers or tumor cell invasion, validating the RPN11 metalloprotease as a promising drug target for cancer therapy [80,81,132,133]. This evidence concerns the gene PSMD14 and neoplasm.